On 28 April 2017 BioInvent International AB (OMXS: BINV) reported that the European Patent Office, EPO, has communicated its intention to grant the company a patent relating to the immune-oncology antibody BI-1206 (Press release, BioInvent, APR 28, 2017, View Source [SID1234518727]). This patent is important since it covers the use of the company’s drug candidate BI-1206, and similarCD32b antibodies, in combination with a CD19, CD20 or CD40 antibody in the treatment of cancer or inflammatory diseases in certain groups of patients. Such a CD20 antibody may, for example, be rituximab. Schedule your 30 min Free 1stOncology Demo! The European patent will be granted by the EPO once all remaining administrative actions have been completed by BioInvent. The maximum patent term expires in 2031.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company has earlier been granted a corresponding patent in Australia and has patent applications pending in other countries.